Zenotech Laboratories

Zenotech Laboratories FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -175.59 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 100.22 % — a change of -275.21% (lower).

FCF Conversion

-175.59 %

YoY

-275.21%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Zenotech Laboratories is 2026 -175.59 % . FCF Conversion Rate (FCF/EBITDA) of Zenotech Laboratories was 2025 100.22 % . It decreases by -275.21% lower compared to the previous year.

The Zenotech Laboratories FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
1,025.81 INR
Jan 1, 2020
-96.20 INR
Jan 1, 2021
-68.27 INR
Jan 1, 2022
70.93 INR
Jan 1, 2023
124.58 INR
Jan 1, 2024
91.45 INR
Jan 1, 2025
100.22 INR
Jan 1, 2026
-175.59 INR
The Zenotech Laboratories FCF Conversion history
YEARFCF ConversionYoY
-175.59 %-275.21%
100.22 %+9.59%
91.45 %-26.59%
124.58 %+75.63%
70.93 %-203.91%
-68.27 %-29.04%
-96.20 %-109.38%
1,025.81 %+505.55%
169.40 %-3,723.03%
-4.68 %-118.62%
25.11 %-35.09%
38.68 %-40.00%
64.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

FCF Conversion Rate (FCF/EBITDA) of Zenotech Laboratories is -175.59 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Zenotech Laboratories changed from 100.22 % to -175.59 %, representing a -275.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Zenotech Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories